With the advent of large scale genome sequencing efforts along with more sophisticated methods of genetic mapping, a number of loci have been identified that are associated with human diseases. Intriguingly, many genes identified in these loci remain uncharacterized. Although current annotation can provide a prediction of putative function of some of these proteins at a biochemical level, understanding their cellular roles require analysis at a single gene level. Bioinformatic analysis carried out in the laboratory during studies on cyclic nucleotide metabolism in mycobacteria identified putative Class III cyclic nucleotide phosphodiesterases (Class III cNMP PDEs) from the non-redundant database of proteins. One of the proteins identified was the Rv0805 gene product from Mycobacterium tuberculosis. Detailed biochemical characterization of this protein revealed that Rv0805 is indeed a phosphodiesterase (PDE) and could hydrolyze 3’, 5’-cyclic adenosine monophosphate (cAMP) as well as 3’, 5’-cyclic guanosine monophosphate (cGMP). Structural analysis of Rv0805 revealed a metallophosphoesterase (MPE) like fold and presence of two metal atoms at the binuclear metal centre of the protein. Moreover, overexpression of Rv0805 in E. coli and M. smegmatis reduced intracellular cAMP levels indicating that it possesses cAMP PDE activity in vivo. The majority of proteins identified in this bioinformatic analysis were of bacterial or archaebacterial in origin but it was interesting to find some mammalian proteins, since, till date, no Class III cNMP PDE has been found in higher eukaryotes. Interestingly, two genes were identified in the human genome. These genes, 239FB and 239AB, are expressed in the fetal brain and adult brain, respectively and have been annotated as metallophosphoesterases but there has been no biochemical or functional characterization of these proteins. The 239FB gene is present between the FSHB and PAX6 genes on chromosome 11. This gene locus is present within a deletion interval (11p13-14) that is associated with the mental retardation phenotype of WAGR syndrome (Wilms’ tumor, aniridia, genitourinary anomalies, mental retardation). Inspection of available sequenced mammalian genomes indicated a shared synteny of the genes in the WAGR locus, highlighting it’s evolutionary conservation. Most interestingly, nucleotide sequences within the WAGR locus (which include the 5 genes WT1, PAX6, RCN1, ELP4 and 239FB) are amongst the 481 ultra conserved regions of the human genome. Moreover, 239FB is one of only 24 instances where an ortholog of an ultra-conserved element could be partially traced back by sequence similarity in lower eukaryotes such as Ciona intestinalis, Drosophila melanogaster, or Caenorhabditis elegans. Although the function of the 239FB protein is unknown so far, the distinctive expression of the gene in the fetal brain and the presence of an “ancient conserved region” in this gene suggest that this gene may be vital for the development of the nervous system. The work carried out in this thesis has attempted to understand the physiological functions of the 239FB/AB gene family. Amino acid sequence comparison revealed two amino acids changes between the human and rat proteins indicating the extra-ordinary sequence conservation of these proteins. Therefore, to characterize the biochemical properties of 239FB and 239AB proteins, rat proteins were used as model enzymes. Reverse transcription-PCR analysis of RNA prepared from the fetal and adult rat brains as well as Western blot analysis on cytosolic fractions of rat brains from various developmental stages indicated that 239FB is predominantly expressed in fetal brain. Detailed biochemical analyses of the rat 239FB and 239AB proteins were performed which showed that they possess metallophosphodiesterase activity. 239FB showed activity only in the presence of Mn2+ and Co2+ as the added metal cofactors. Surprisingly, the Km for Mn2+ of 239FB was found to be 1.5 mM, which is nearly 60-fold higher than that of its mycobacterial ortholog, Rv0805. A systematic mutational analysis was performed to characterize the residues that are involved in binding either one or both the metals found in the catalytic site of 239FB. Although 239FB shares some of the residues that have been shown to be essential for metal binding and catalytic activity with other MPEs including Rv0805, there are some differences as well. One histidine residue that has been conserved in other MPEs and has been shown to be important for metal binding is replaced by glycine (Gly-252) in 239FB. To study the consequence of replacing the glycine with a histidine in 239FB, a 239FBGly252His mutant protein was generated and characterized. Interestingly, the single mutation of Gly-252 to a histidine residue not only increased the affinity of the protein for metals but increased catalytic activity as well with various phosphodiesters. Moreover, 239FBGly252His mutant protein showed significant activity with cAMP and cGMP which were not hydrolysed by wild type 239FB. Interestingly, in the 239AB protein, histidine 284 is present at a position equivalent to Gly-252 in the 239FB protein. Biochemical characterization of 239AB showed 2’, 3’-cAMP hydrolyzing activity similar to 239FBGly252His mutant protein. A rat 239FB protein with a mutation (His67Arg) corresponding to a single nucleotide polymorphism seen in human 239FB, led to complete inactivation of the protein. The occurrence of this SNP at a very low frequency and only as a heterozygous condition suggests that a complete loss-of-function mutation of 239FB in human populations cannot be tolerated. To gain insights into the function of 239FB in its physiological milieu, yeast two-hybrid screening was performed with 239FB using human fetal brain cDNA library. Dipeptidyl peptidase III, a zinc dependent metallopeptidase, was found as an interacting partner of 239FB in this analysis and the functional consequences of this interaction would be an interesting area of study in future. While a number of metallophosphoesterases have been characterized biochemically and structurally, their biological role(s) and in vivo substrate(s) remain elusive. In order to elucidate the physiological role of 239FB/AB family, the ortholog of 239FB/AB in D. melanogaster was characterized. Sequence comparison of Drosophila ortholog with both the mammalian proteins indicated that it may be an ortholog of 239AB and hence, it was named as d239AB. Enhancer-promoter analysis with a putative promoter region of the d239AB indicated the expression of d239AB in the mushroom bodies in brain and in enterocytes in mid gut. Characterization of a Drosophila line, BS#16242, with a piggybac element inserted in the intron of d239AB showed disruption of d239AB expression. This suggested that BS#16242 line can serve as a d239AB knockout line and hence, was selected for further phenotypic characterization to unravel the physiological roles of d239AB. Though, BS#16242 flies did not show any developmental defects, a severe reduction in the fecundity of these files was observed. Further analysis revealed defective ovulation as a probable reason for reduced fecundity of these flies. In addition to compromised fecundity, BS#16242 flies showed a significant reduction in the life span of male as well as female flies. Moreover, these flies showed less resistance to thermal stress and desiccation. Most interestingly, all these phenotypes were rescued upon neuronal expression of the d239AB transgene in BS#16242 flies indicating that neuronal function of d239AB is important for diverse physiological processes. The phenotypes observed in BS#16242 flies mimic the physiological state under increased insulin signaling, such as decrease in life span, and susceptibility to various stress conditions suggesting that d239AB could play a role in the insulin signaling pathway. Interestingly, overexpression of d239AB transgene in neurons reduced cAMP levels in the brains of Drosophila, indicating that the protein may have cAMP phosphodiesterase activity in vivo. This is the first analysis of the presence of a Class III phosphodiesterase in eukaryotes. Thus, d239AB mediated regulation of cAMP levels in a particular subsets of cells, such as neurons, could also be one of the molecular mechanisms responsible for reduced fecundity and longevity of BS#16242 flies. Interacting partners of d239AB were inspected in the Drosophila interactome (built on protein-protein interactions identified using a yeast two-hybrid approach). Strikingly, most of the d239AB interacting proteins were involved either in transcriptional or translational regulation indicating that d239AB could be involved in the regulation of expression of genes involved in diverse physiological processes. This could explain why disruption of d239AB led to various physiological defects such as reduced fecundity, decreased life span and compromised fitness. In summary, studies described in this thesis suggest that 239FB and 239AB proteins are the first Class III cyclic nucleotide phosphodiesterases reported in eukaryotes. Results shown here suggest the critical role of their ortholog in the physiology of Drosophila. Further genetic manipulation in D. melanogaster and other organisms which harbor orthologs of the 239FB/AB gene could throw light on the diverse biological roles of these enzymes in humans.

In this work, the influence of the second messenger cAMP on the functional plasticity of M-DC8+ dendritic cells (DC) was examined. The marker M-DC8 defines a population of native DC first described in blood. After their isolation, M-DC8+ DC acquire a mature CD83+ phenotype during a short culture ex vivo. After a challenge with LPS and IFN-g, M-DC8+ DC secrete large amounts of the proinflammatory cytokines IL-12(p70) and TNF-a surpassing by far other DC populations and monocytes. Due to their preferential induction of TH1-dominated T cell responses, M-DC8+ DC might play a role in the pathogenesis of inflammatory diseases. Different cAMP-elevating agents suppressed the proinflammatory cytokine production and enhanced the secretion of anti-inflammatory IL-10. Activity of phosphodiesterase (PDE) 4, the most important cAMP-hydrolysing enzyme in immune cells, was detected and RT-PCR revealed the expression of PDE4 subtypes 4A, 4B and 4D in M-DC8+ DC, whereas 4C was not detectable. The PDE4-specific inhibitors AWD12-281 and Roflumilast were then used to elevate cAMP concentrations. These substances have been proven to be efficient in anti-inflammatory therapies. In the presence of PDE4 inhibitors, the LPS/IFN-g-induced production of IL-12 and TNF-a was decreased by 90 % and 60 %, respectively, whereas the IL-10-release was doubled. These effects were only observed, if the PDE4 inhibitors where present from the beginning of the culture. The inhibition of the IL-12 secretion was reverted using an a-IL-10-receptor antibody. PDE4 inhibitor-treated M-DC8+ DC showed a reduced capacity to polarize TH1-cells, which was demonstrated analysing culture supernatants by ELISA and by single-cell analysis detecting intracellular IFN-g und IL-4. These results suggest that PDE4 inhibitors may not only be useful in the therapy of TH2-mediated diseases but also in TH1-dominated indications such as multiple sclerosis and Crohn´s disease. Despite the shift of the cytokine profile, the in vitro maturation of M-DC8+ DC was not affected by PDE4 inhibitors. The expression of CD83, CD80, CD86, MHC-molecules as well as CD54 and CD58, was assessed by FACS analysis. Correspondingly, in the presence of AWD12-281, M-DC8+ DC efficiently stimulated the proliferation of allogeneic CD4+CD45RA+ T-cells. In the second part of this study, the effects of an inhibition of cAMP-synthesis in M-DC8+ DC were analyzed. Two adenylyl cyclase (AC) inhibitors, 2,5-Dideoxyadenosine and SQ22536, clearly hampered the in vitro maturation of M-DC8+ DC. The expression of the DC maturation marker CD83 could be reconstituted using the stable cAMP-analogon 8-Br-cAMP. Measuring the intracellular cAMP concentration in M-DC8+ DC, initially low cAMP-levels were observed, but within 30 min the concentration raised and returned to original levels within 2 hrs. Blocking the cAMP synthesis by AC inhibitors, the LPS/IFN-g-induced production of IL-12, TNF-a and IL-10 was strongly reduced. Furthermore, it was demonstrated that M-DC8+ DC can only release IL-12 after a transient elevation of cAMP, i.e. they acquire a "license". Such a regulation of the IL-12 production has not been described before. Protein kinase A is an important effector molecule of cAMP. Inhibiting its activity resulted in a reduced expression of the DC maturation marker CD83 and a lower cytokine production underlining the importance of cAMP-signalling for the activation of M-DC8+ DC. In conclusion, this study provides evidence for a new concept of the immune-regulatory function of cAMP. Here, cAMP is essentially involved in the initial activation and maturation of DC and enables them to secrete large amounts of IL-12 and TNF-a upon stimulation with a TLR ligand. Conversely, a long-term elevation of cAMP-concentrations inhibits the proinflammatory effector functions of M-DC8+ DC and can induce anti-inflammatory responses by enhancing the secretion of IL-10. / In dieser Arbeit wurde der Einfluss des second messengers cAMP auf die funktionelle Plastizität von M-DC8+ dendritischen Zellen (DC) untersucht. Der Oberflächenmarker M-DC8 definiert eine zunächst im Blut beschriebene Population nativer DC. Nach ihrer Isolation erlangen M-DC8+ DC während einer kurzen Kultur einen maturen CD83+ Phänotyp. Nach Stimulation mit LPS und IFN-g produzieren native M-DC8+ DC deutlich höhere Mengen der proinflammatorischen Zytokine IL-12(p70) und TNF-a als andere DC-Populationen oder Monozyten. Dies resultiert in einer Programmierung TH1-dominierter T-Zellantworten. M-DC8+ DC könnten daher an der Pathogenese entzündlicher Krankheiten beteiligt sein. Unterschiedliche cAMP-erhöhende Substanzen supprimierten die proinflammatorische Zytokinproduktion und verstärkten gleichzeitig die Sekretion des anti-inflammatorischen IL-10. In M-DC8+ DC konnte die Aktivität von Phosphodiesterase (PDE) 4, dem wichtigsten cAMP-hydrolysierenden Enzym in Immunzellen, nachgewiesen werden. Durch RT-PCR wurde die Expression der PDE4-Subtypen 4A, 4B und 4D gezeigt, nicht aber 4C. Zur Erhöhung der cAMP-Konzentration wurden dann die PDE4-spezifischen Inhibitoren AWD12-281 und Roflumilast eingesetzt, deren klinische Effizienz bei anti-inflammatorischen Therapien belegt ist. Auch diese Substanzen verringerten die LPS/IFN-g-induzierte Produktion von IL-12 und TNF-a durch M-DC8+ DC um 90 % bzw. 60 %, während die IL-10-Freisetzung etwa verdoppelt wurde. Diese starken Effekte konnten nur erzielt werden, wenn die PDE4-Inhibitoren von Beginn der Kultur an eingesetzt wurden. Die Hemmung der IL-12-Sekretion wurde in Gegenwart eines a-IL-10-Rezeptor-Antikörpers aufgehoben. Unter dem Einfluss von PDE4-Inhibitoren war die TH1-Programmierung durch M-DC8+ DC deutlich reduziert, was sowohl durch die Analyse der Zellüberstände mittels ELISA als auch auf Einzelzell-Ebene durch intrazelluläre Detektion von IFN-g und IL-4 nachgewiesen wurde. Diese Ergebnisse legen nahe, dass PDE4-Inhibitoren nicht nur für TH2-vermittelte Erkrankungen sondern auch für TH1-dominierte Indikationen wie Multiple Sklerose oder Morbus Crohn von Nutzen sein könnten. Trotz der starken Modulation des Zytokinprofils blieb die in vitro-Ausreifung M-DC8+ DC unbeeinflusst von PDE4-Inhibitoren. Untersucht wurde die Expression von CD83, CD80, CD86, MHC-Molekülen, CD54 und CD58 mittels FACS-Analyse. Entsprechend induzierten M-DC8+ DC auch in Anwesenheit von AWD12-281 die Proliferation allogener CD4+CD45RA+ T-Zellen. Im zweiten Teil der Arbeit wurde untersucht, wie sich die Blockade der cAMP-Synthese auf M-DC8+ DC auswirkt. Zwei Adenylatcyclase-Inhibitoren, 2,5-Dideoxyadenosine und SQ22536, hemmten die in vitro-Maturation von M-DC8+ DC deutlich. Die CD83-Expression wurde mit 8-Br-cAMP rekonstituiert. Messungen der intrazellulären cAMP-Konzentration in unbehandelten M-DC8+ DC zeigten initial niedrige cAMP-Spiegel, die innerhalb von 30 min anstiegen und nach 2 h wieder auf das Ausgangsniveau abfielen. Die LPS/IFN-g-induzierte Produktion von IL-12, TNF-a und IL-10 wurde durch AC-Inhibitoren deutlich vermindert. M-DC8+ DC erhalten nur nach einer transienten cAMP-Erhöhung die "Lizenz" IL-12 freizusetzen. Eine derartige Regulation der IL-12-Sekretion ist bisher nicht beschrieben. Eine Hemmung des cAMP-Effektormoleküls Proteinkinase A resultierte in der reduzierten Expression des DC-Maturationsmarkers CD83 und einer verringerten Zytokinproduktion. Dies unterstreicht die Bedeutung von cAMP für die Aktivierung M-DC8+ DC. Zusammenfassend gibt diese Arbeit am Beispiel nativer humaner DC Anhalt für ein neues Konzept der immunregulatorischen Funktion von cAMP. Hierbei ist cAMP wesentlich an der Ausreifung von M-DC8+ DC beteiligt, woraufhin diese große Mengen IL-12 und TNF-a sekretieren können. Dagegen wirkt eine langfristige cAMP-Erhöhung durch die Induktion von IL-10 anti-inflammatorisch.

In this work, the influence of the second messenger cAMP on the functional plasticity of M-DC8+ dendritic cells (DC) was examined. The marker M-DC8 defines a population of native DC first described in blood. After their isolation, M-DC8+ DC acquire a mature CD83+ phenotype during a short culture ex vivo. After a challenge with LPS and IFN-g, M-DC8+ DC secrete large amounts of the proinflammatory cytokines IL-12(p70) and TNF-a surpassing by far other DC populations and monocytes. Due to their preferential induction of TH1-dominated T cell responses, M-DC8+ DC might play a role in the pathogenesis of inflammatory diseases. Different cAMP-elevating agents suppressed the proinflammatory cytokine production and enhanced the secretion of anti-inflammatory IL-10. Activity of phosphodiesterase (PDE) 4, the most important cAMP-hydrolysing enzyme in immune cells, was detected and RT-PCR revealed the expression of PDE4 subtypes 4A, 4B and 4D in M-DC8+ DC, whereas 4C was not detectable. The PDE4-specific inhibitors AWD12-281 and Roflumilast were then used to elevate cAMP concentrations. These substances have been proven to be efficient in anti-inflammatory therapies. In the presence of PDE4 inhibitors, the LPS/IFN-g-induced production of IL-12 and TNF-a was decreased by 90 % and 60 %, respectively, whereas the IL-10-release was doubled. These effects were only observed, if the PDE4 inhibitors where present from the beginning of the culture. The inhibition of the IL-12 secretion was reverted using an a-IL-10-receptor antibody. PDE4 inhibitor-treated M-DC8+ DC showed a reduced capacity to polarize TH1-cells, which was demonstrated analysing culture supernatants by ELISA and by single-cell analysis detecting intracellular IFN-g und IL-4. These results suggest that PDE4 inhibitors may not only be useful in the therapy of TH2-mediated diseases but also in TH1-dominated indications such as multiple sclerosis and Crohn´s disease. Despite the shift of the cytokine profile, the in vitro maturation of M-DC8+ DC was not affected by PDE4 inhibitors. The expression of CD83, CD80, CD86, MHC-molecules as well as CD54 and CD58, was assessed by FACS analysis. Correspondingly, in the presence of AWD12-281, M-DC8+ DC efficiently stimulated the proliferation of allogeneic CD4+CD45RA+ T-cells. In the second part of this study, the effects of an inhibition of cAMP-synthesis in M-DC8+ DC were analyzed. Two adenylyl cyclase (AC) inhibitors, 2,5-Dideoxyadenosine and SQ22536, clearly hampered the in vitro maturation of M-DC8+ DC. The expression of the DC maturation marker CD83 could be reconstituted using the stable cAMP-analogon 8-Br-cAMP. Measuring the intracellular cAMP concentration in M-DC8+ DC, initially low cAMP-levels were observed, but within 30 min the concentration raised and returned to original levels within 2 hrs. Blocking the cAMP synthesis by AC inhibitors, the LPS/IFN-g-induced production of IL-12, TNF-a and IL-10 was strongly reduced. Furthermore, it was demonstrated that M-DC8+ DC can only release IL-12 after a transient elevation of cAMP, i.e. they acquire a "license". Such a regulation of the IL-12 production has not been described before. Protein kinase A is an important effector molecule of cAMP. Inhibiting its activity resulted in a reduced expression of the DC maturation marker CD83 and a lower cytokine production underlining the importance of cAMP-signalling for the activation of M-DC8+ DC. In conclusion, this study provides evidence for a new concept of the immune-regulatory function of cAMP. Here, cAMP is essentially involved in the initial activation and maturation of DC and enables them to secrete large amounts of IL-12 and TNF-a upon stimulation with a TLR ligand. Conversely, a long-term elevation of cAMP-concentrations inhibits the proinflammatory effector functions of M-DC8+ DC and can induce anti-inflammatory responses by enhancing the secretion of IL-10. / In dieser Arbeit wurde der Einfluss des second messengers cAMP auf die funktionelle Plastizität von M-DC8+ dendritischen Zellen (DC) untersucht. Der Oberflächenmarker M-DC8 definiert eine zunächst im Blut beschriebene Population nativer DC. Nach ihrer Isolation erlangen M-DC8+ DC während einer kurzen Kultur einen maturen CD83+ Phänotyp. Nach Stimulation mit LPS und IFN-g produzieren native M-DC8+ DC deutlich höhere Mengen der proinflammatorischen Zytokine IL-12(p70) und TNF-a als andere DC-Populationen oder Monozyten. Dies resultiert in einer Programmierung TH1-dominierter T-Zellantworten. M-DC8+ DC könnten daher an der Pathogenese entzündlicher Krankheiten beteiligt sein. Unterschiedliche cAMP-erhöhende Substanzen supprimierten die proinflammatorische Zytokinproduktion und verstärkten gleichzeitig die Sekretion des anti-inflammatorischen IL-10. In M-DC8+ DC konnte die Aktivität von Phosphodiesterase (PDE) 4, dem wichtigsten cAMP-hydrolysierenden Enzym in Immunzellen, nachgewiesen werden. Durch RT-PCR wurde die Expression der PDE4-Subtypen 4A, 4B und 4D gezeigt, nicht aber 4C. Zur Erhöhung der cAMP-Konzentration wurden dann die PDE4-spezifischen Inhibitoren AWD12-281 und Roflumilast eingesetzt, deren klinische Effizienz bei anti-inflammatorischen Therapien belegt ist. Auch diese Substanzen verringerten die LPS/IFN-g-induzierte Produktion von IL-12 und TNF-a durch M-DC8+ DC um 90 % bzw. 60 %, während die IL-10-Freisetzung etwa verdoppelt wurde. Diese starken Effekte konnten nur erzielt werden, wenn die PDE4-Inhibitoren von Beginn der Kultur an eingesetzt wurden. Die Hemmung der IL-12-Sekretion wurde in Gegenwart eines a-IL-10-Rezeptor-Antikörpers aufgehoben. Unter dem Einfluss von PDE4-Inhibitoren war die TH1-Programmierung durch M-DC8+ DC deutlich reduziert, was sowohl durch die Analyse der Zellüberstände mittels ELISA als auch auf Einzelzell-Ebene durch intrazelluläre Detektion von IFN-g und IL-4 nachgewiesen wurde. Diese Ergebnisse legen nahe, dass PDE4-Inhibitoren nicht nur für TH2-vermittelte Erkrankungen sondern auch für TH1-dominierte Indikationen wie Multiple Sklerose oder Morbus Crohn von Nutzen sein könnten. Trotz der starken Modulation des Zytokinprofils blieb die in vitro-Ausreifung M-DC8+ DC unbeeinflusst von PDE4-Inhibitoren. Untersucht wurde die Expression von CD83, CD80, CD86, MHC-Molekülen, CD54 und CD58 mittels FACS-Analyse. Entsprechend induzierten M-DC8+ DC auch in Anwesenheit von AWD12-281 die Proliferation allogener CD4+CD45RA+ T-Zellen. Im zweiten Teil der Arbeit wurde untersucht, wie sich die Blockade der cAMP-Synthese auf M-DC8+ DC auswirkt. Zwei Adenylatcyclase-Inhibitoren, 2,5-Dideoxyadenosine und SQ22536, hemmten die in vitro-Maturation von M-DC8+ DC deutlich. Die CD83-Expression wurde mit 8-Br-cAMP rekonstituiert. Messungen der intrazellulären cAMP-Konzentration in unbehandelten M-DC8+ DC zeigten initial niedrige cAMP-Spiegel, die innerhalb von 30 min anstiegen und nach 2 h wieder auf das Ausgangsniveau abfielen. Die LPS/IFN-g-induzierte Produktion von IL-12, TNF-a und IL-10 wurde durch AC-Inhibitoren deutlich vermindert. M-DC8+ DC erhalten nur nach einer transienten cAMP-Erhöhung die "Lizenz" IL-12 freizusetzen. Eine derartige Regulation der IL-12-Sekretion ist bisher nicht beschrieben. Eine Hemmung des cAMP-Effektormoleküls Proteinkinase A resultierte in der reduzierten Expression des DC-Maturationsmarkers CD83 und einer verringerten Zytokinproduktion. Dies unterstreicht die Bedeutung von cAMP für die Aktivierung M-DC8+ DC. Zusammenfassend gibt diese Arbeit am Beispiel nativer humaner DC Anhalt für ein neues Konzept der immunregulatorischen Funktion von cAMP. Hierbei ist cAMP wesentlich an der Ausreifung von M-DC8+ DC beteiligt, woraufhin diese große Mengen IL-12 und TNF-a sekretieren können. Dagegen wirkt eine langfristige cAMP-Erhöhung durch die Induktion von IL-10 anti-inflammatorisch.